{'fraction_non_alphanumeric': 0.0137524557956778, 'fraction_numerical': 0.004911591355599214, 'mean_word_length': 5.175757575757576, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Economic evaluation of outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service.

OBJECTIVE
To analyze the costs related to visits and drug prescription in outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service.


SUBJECTS AND METHODS
A prospective and experimental study was carried out. Seventy one patients were divided into two groups: control and pharmaceutical care. Patients in the pharmaceutical care group were followed up monthly by a single clinical pharmacist.


RESULTS
The pharmaceutical care group had a statistically significant reduction in costs of metformin and emergency department visits, and increased costs with their family physicians. On the other hand, the control group had a statistically significant increase of 21.3% in the general costs of treatment and visits.


CONCLUSION
The pharmaceutical care group maintained the same costs related to drugs and visits, while the control group showed a significant increase in general costs.